Chronic immune-related adverse events often persist years after adjuvant anti–PD-1 immunotherapy for high-risk melanoma and may require prolonged monitoring and management, researchers say.
The transition from psoriasis to PsA - and the early diagnosis of PsA - is of considerable scientific and clinical interest. People typically have psoriatic skin disease for a decade or more before they begin to experience the joint involvement of PsA.